Ann: Company Update, page-15

That's the problem though for a drug without approval and only 8 week phase II trial in 70 patients that still hasn't shown the measures MS drugs have been approved on who will cover the costs ?

In respect of being unapproved it then remains an experimental treatment right ?

I think you will struggle to find any government let alone insurance companies willing to cover costs but again happy to be proven wrong.

An approved drug though and one under PBS (or the like) sure it covers the lion share that's why being granted PBS is such a big deal for companies there market increases many multiples. In Australia use Copaxone & Tysabri for example as they are roughly the same costs say $30K pa but after PBS it comes down for the patient to between $70 & $400 each year.

On a plus side I guess they say they are focussing on Europe and I think in Europe far less drugs are covered by the government so probably takes a lot of the cheap options for patients out of the picture.